- $12.51m
- -$43.35m
- 28
- 55
- 27
- 29
Annual income statement for NextCure, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 22.4 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 63.6 | 70.8 | 75.9 | 67.6 | 59.7 |
| Operating Profit | -41.2 | -70.8 | -75.9 | -67.6 | -59.7 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -36.6 | -69.4 | -74.7 | -62.7 | -55.7 |
| Net Income After Taxes | -36.6 | -69.4 | -74.7 | -62.7 | -55.7 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -36.6 | -69.4 | -74.7 | -62.7 | -55.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -36.6 | -69.4 | -74.7 | -62.7 | -55.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.33 | -2.51 | -2.69 | -2.25 | -1.9 |